Anokion puts liver to the test

Anokion’s preclinical data showcase induction of immune tolerance via liver-targeted autoantigens

Data presented Sept. 13 at a major multiple sclerosis meeting showcased the ability of Anokion’s liver targeting technology to induce immune tolerance.

Armed with a fresh $40 million series B round, Anokion S.A. is developing a platform to treat autoimmune disease by

Read the full 414 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE